We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Potent Metastasis Suppressor Gene Identified

By Biotechdaily staff writers
Posted on 04 Dec 2002
Researchers using DNA microarray technology to evaluate the expression profile of cancer-related genes in 105 pathologically characterized tumors from seven common organ sites have found that the RhoGDI2 gene is a metastasis suppressor, a marker of aggressive human cancer and a promising target for therapy. More...
Their finding was published in the November 15, 2002, issue of Cancer Research.

The investigators, from the University of Virginia Health Sciences Center (Charlottesville, USA; www.virginia.edu), transplanted the RhoGDI2 gene into a series of aggressive cancer lines. They found that while the cells continued to grow normally, they lost their ability to metastasize. The protein produced by RhoGDI2 prevents the cancer cell from undergoing metastasis. A diagnostic test to determine its presence or absence in cancerous tissue could help to guide treatment of the disease.

"We found the greatest RhoGDI2 loss in invasive and metastatic cancer tissue. At this point, it is clear the gene plays a role in the cancer's lethal progression to metastasis and not in the initial formation of the cancer,” explained senior author Dr. Dan Theodorescu, professor of urology and molecular physiology at the University of Virginia. "As such, it is one of only a handful of true metastasis suppressor genes known.”




Related Links:
University of Virginia Health System

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Clinical Informatics Platform
CLARION™
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.